Zogenix — Corporate Update (April 2016)
24 slides from Zogenix's corporate update, Apr 20, 2016
Slide 1: Corporate Update April 2016
Corporate Update April 2016 NASDAQ: ZGNX Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "plans," "expects," "will," "potential" and similar expressions are intended to identify forward-looki
Slide 3: Late Stage Development Opportunities
Late Stage Development Opportunities EPILEPSY (DRAVET SYNDROME) Phase 3 Initiated January 2016 SCHIZOPHRENIA Phase 3 Ready ONCE-MONTHLY ZX008 (low-dose fenfluramine) Products for the Treatment of CENTRAL NERVOUS SYSTEM (CNS) Disorders
Slide 4: The Zogenix Opportunity
The Zogenix Opportunity PROMISING PIPELINE of Differentiated CNS Compounds in Late-Stage Clinical Development ORPHAN DRUG STRATEGY Focused on Solving Significant Treatment Gaps FULLY FUNDED Through 2017 for ZX008 Phase 3 Data, NDA and MAA Submissions PHASE 3 PROGRAM INITIATED for ZX008, Fast Track D
Slide 5: ZX008 Dravet Syndrome
Worldwide Rights Orphan Drug Designation in U.S. and E.U. IND Approved Dec. 2015; Phase 3 Initiation Jan. 2016 Fast Track Designation Intend to Commercialize Directly in U.S. and E.U. Asia-Pacific Partnering Opportunity ZX008 Dravet Syndrome
Slide 6: Dravet Syndrome: A Catastrophic Illness
Dravet Syndrome: A Catastrophic Illness Estimated 16,000 - 29,000 patients in the U.S. and E.U.1 Approximately 75 specialty treatment centers in U.S. and similar in E.U. Does not effectively respond to traditional epilepsy medications Higher incidence of status epilepticus and SUDEP compared to othe
Slide 7: Low Dose Fenfluramine: Long Term Efficacy and Safety in Treating Dravet Syndrome
Low Dose Fenfluramine: Long Term Efficacy and Safety in Treating Dravet Syndrome Overview Long-term open-label study of fenfluramine as an adjunctive anticonvulsant therapy Published in Epilepsia in 2012 12 Dravet syndrome patients (11 with confirmatory genetic mutation) Age 9 months to 13 years at
Slide 8: Five Year Follow-up (2010 – 2014) on Patients First Reported in Epilepsia
Five Year Follow-up (2010 – 2014) on Patients First Reported in Epilepsia (2012) Overview Follow-up analysis of original cohort still treated (n=10) Mean duration of treatment = 16.1 years (6 - 27) Efficacy 3 patients seizure-free for all 5 yrs 4 additional patients had seizure-free periods of > 2 y
Slide 9: Prospective Study of a New Cohort Confirms Earlier Findings of Efficacy
Prospective Study of a New Cohort of Patients Confirms Earlier Findings of Efficacy Presented at American Epilepsy Society Meeting 2015 % Reduction in tonic-clonic seizures Patient Number 0 -20 -40 -60 -80 -100 1 2 3 4 5 6 7 Patients with Dravet syndrome who started fenfluramine after 2010 Duration
Slide 10: Preclinical & Clinical Evidence for Role of Serotonin in Seizure Control
Preclinical & Clinical Evidence for Role of Serotonin in Seizure Control Preclinical data ↑ extracellular 5-HT levels inhibits many types of seizures in rodent models Identification of 5HT receptors involved in Dravet syndrome seizure control Several AED’s (i.e. valproic acid, topirimate) ↑ 5HT Bonn
Slide 11: Pre-Clinical Evidence of Fenfluramine Activity in a Model of Dravet Syndrome
Pre-Clinical Evidence of Fenfluramine Activity in a Preclinical Model of Dravet Syndrome Identified 5-HT Receptor Subtypes (1D, 2C and 2A) Responsible for Fenfluramine’s Putative Mechanism-of-Action in Dravet Syndrome2 1 Zhang, Yifen et al. Pharmacological Characterization of an Antisense Knockdown
Slide 12: ZX008 Phase 3 Clinical Studies
ZX008 Phase 3 Clinical Studies 6 WEEKS BASELINE OBSERVATION 12 WEEKS TREATMENT Initial Screen Placebo Open Label Safety Study N = 105 Ages 2 – 18 ZX008 0.8 mg/kg/d ZX008 0.2 mg/kg/d 1:1:1 Randomization 2 week Titration Two Identical Safety and Efficacy Studies US/Canada: Initiated Jan 2016 (1501) Eu
Slide 13: Key Assessments
Key Assessments Adverse events Laboratory safety parameters (hematology, chemistry, urinalysis) Vital signs Cardiac examination (baseline, midway, and endpoint) 3 Doppler echocardiograms 12-lead electrocardiogram SAFETY Analyses for ZX008 0.8 mg/kg/day vs. Placebo, and ZX008 0.2 mg/kg/day vs. Placeb
Slide 14: Other ZX008 Clinical Studies Focused on Market Access in Europe
Other ZX008 Clinical Studies Focused on Market Access in Europe Maintaining orphan exclusivity in EU requires a demonstration of incremental benefit over stiripentol Stiripentol is an approved orphan drug for the adjunctive treatment of Dravet syndrome in a specific combination with valproate and cl
Slide 15: Establishing Product Protection
Establishing Product Protection ORPHAN DRUG STATUS Provides 10 Years of Market Exclusivity in E.U. and 7 Years in U.S. If Obtained in Japan, ODS Will Provide 10 Years Exclusivity PATENTS PENDING(1) Use of Fenfluramine in Dravet Syndrome and Elements of a Future REMS Program Ongoing Preclinical and D
Slide 16: Exploring Other Opportunities in Pediatric Refractory Epilepsy Syndromes
Exploring Other Opportunities in Pediatric Refractory Epilepsy Syndromes ZX008 Lennox Gastaut Syndrome Other Pediatric Orphan Refractory Epilepsy Conditions Investigator Initiated Study (IIS) Started March 2016 Plan to Evaluate in 2H 2016 (IIS and/or Phase 2)
Slide 17: Proprietary Subcutaneous Once-Monthly Antipsychotic
Proprietary Subcutaneous Once-Monthly Antipsychotic Highly Differentiated Profile Worldwide Rights Search for Development and Commercialization Partner Initiated Schizophrenia PHASE 3 READY
Slide 18: Market Overview: RELDAY
Market Overview: RELDAY 2.4 million diagnosed patients in the U.S. Treatment compliance can be challenging Treatment paradigm evolving towards earlier use of LAIs Long Acting Injection (LAI) for Schizophrenia PATIENTS PHYSICIANS Large, Growing $3.8B WW Market Highly concentrated U.S. market 11,000 p
Slide 19: RELDAY Has a Differentiated LAI Profile
RELDAY Has a Differentiated LAI Profile Overcomes complexities associated with other long acting injections No oral supplementation / complicated loading dose regimens Initiation dose identical to maintenance dose Once-monthly dosing interval Subcutaneous administration Potential for improved safety
Slide 20: RELDAY Development Progress
RELDAY Development Progress Strong physician and payer interest Single-dose study successfully completed Multi-dose study successfully completed => Phase 3 ready Issued and pending patents through at least 2034 Formulation technology also amenable to three-month dosing interval for future developmen
Slide 21: Focused on Execution in Late-Stage Development
Focused on Execution in Late-Stage Development ZX008 IIS– Investigator Initiated Study DS – Dravet Syndrome LGS – Lennox Gastaut Syndrome Q1 Q2 Q3 Q4 2017 U.S. Ph 3 Results Results from IIS for LGS Initiate E.U. Ph 3 Trial for DS IIS for LGS Initiate U.S. Ph 3 Trial for DS E.U. Ph 3 Results Potentia
Slide 22: Financial Highlights
Financial Highlights Cash (balance at 12-31-15) $155M Debt (1) (as of 12-31-15) $20M Market Capitalization (as of 4-18-2016) $275M Common Shares Outstanding (as of 12-31-15) 24.8 M Fully Diluted Shares (2) (as of 12-31-15) 29.5 M Excludes $7.0 million working capital advance from Endo International
Slide 23: PROMISING PIPELINE PHASE PROGRAM INITIATED FOR ZX008 EXPERIENCED TEAM IN PLACE FULLY FUNDED CLINICAL
PROMISING PIPELINE PHASE 3 PROGRAM INITIATED FOR ZX008 EXPERIENCED TEAM IN PLACE FULLY FUNDED CLINICAL PROGRAMS SIGNIFICANT NEAR-TERM MILESTONES NASDAQ: ZGNX
Slide 24: NASDAQ: ZGNX NASDAQ: ZGNX
NASDAQ: ZGNX NASDAQ: ZGNX